CELEBREX: THE FIRST SPECIFIC INHIBITOR OF COX-2: NEW DATA

CELEBREX: THE FIRST SPECIFIC INHIBITOR OF COX-2: NEW DATA

Saved in:

Bibliographic Details
Main Author:	E L Nassonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2000-08-01
Series:	Научно-практическая ревматология
Online Access:	https://rsp.mediar-press.net/rsp/article/view/486
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CELEBREX-A SPECIFIC INHIBITOR OF CYCLOOXIGENASE-2: EFFICACY AND TOLERABILITY
by: - -
Published: (2000-04-01)

Celebrex in treatment of joint diseases in patients with risk factors of gastropathy and cardiovascular palhalodydevelopment
by: N. V. Chichasova, et al.
Published: (2004-02-01)

CELEBREX IN TREATMENT OF VERTEBRAL PAIN SYNDROME IN SYSTEMICV LUPUS ERYTHEMATOSUS
by: N. P. Shilkina
Published: (2002-06-01)

CELEBREX IN TREATMENT OF VERTEBRAL PAIN SYNDROME IN SYSTEMICV LUPUS ERYTHEMATOSUS
by: N. P. Shilkina, et al.
Published: (2002-06-01)

Adverse Effects of COX-2 Inhibitors
by: Jagdish N. Sharma, et al.
Published: (2005-01-01)

Molecular Interaction Analysis of Homodihydrocapsaicin as COX-2 Inhibitor
by: Maria Nona Elci Lele, et al.
Published: (2022-06-01)

Design and synthesis of pyridazinone hybrid in PEG-400 as COX-1/COX-2 inhibitor and their antioxidant study
by: Omprakash B. Pawar, et al.
Published: (2025-06-01)

CARDIOVASCULAR EFFECTS OF SELECTIVE COX-2 INHIBITORS IN RHEUMATIC DISEASES
by: Rimma Mikhailovna Balabanova
Published: (2010-06-01)

MELOXICAM (MOVAL1S): THE SELECTIVE INHIBITOR OF COX-2 IN CLINICAL PRACTICE
by: V A Nassonova
Published: (2000-08-01)

TREATMENT OF RHEUMATIC DISEASES INTERRELATION OF SELECTIVE NON-STEROIDAL ANTIINFLAMMATORY DRUG CELEBREX (CELECOXIB) AND INHIBITOR OF ENZYME WITH APF ENAP (ENALAPR1L) IN PATIENTS WITH RHEUMATIC DISEASES AND CONCOMITANT ARTERIAL HYPERTENSION
by: Yu. V. Mouraviev, et al.
Published: (2002-06-01)

Exploring the anti-cancer potential of coumarin derivatives targeting COX-2 inhibitors
by: Thanh Tin Le, et al.
Published: (2025-01-01)

Inhibitors of Mitogen-Activated Protein Kinases Downregulate COX-2 Expression in Human Chondrocytes
by: Riina Nieminen, et al.
Published: (2005-01-01)

The Study of Pyridazine Compounds on Prostanoids: Inhibitors of COX, cAMP Phosphodiesterase, and TXA2 Synthase
by: Mohammad Asif
Published: (2014-01-01)

Phytocompounds in Precision Dermatology: COX-2 Inhibitors as a Therapeutic Target in Atopic-Prone Skin
by: Muhammad Suleman, et al.
Published: (2025-07-01)

A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.
by: Tjeerd-Pieter van Staa, et al.
Published: (2009-12-01)

Do NSAID/COX-2 Inhibitors Increase Nonunion After Fracture Surgery? Dilemma and Consideration In Use
by: Azmi
Published: (2022-10-01)

Inhibition of Angiogenesis In Vitro by Chebulagic Acid: A COX-LOX Dual Inhibitor
by: A. P. Athira, et al.
Published: (2013-01-01)

Immunohistochemical Investigation of Cyclooxygenase-2 Expression in Rabbit Uterine Adenocarcinoma and the Potential Use of COX-2 Inhibitors in Cancer Therapy
by: Emanuela Vaccaro, et al.
Published: (2024-11-01)

Modification and Characterization of Some New Levofloxacin Heterocyclic Derivatives as COX-2 Enzyme Inhibitors and Evaluate Their Efficacy Pharmacokinetics by Molecular Docking and the Swiss ADME Studies
by: Mustafa Moaied Rabeaa, et al.
Published: (2024-04-01)

Analysis of Gene Expression in Human Dermal Fibroblasts Treated with Senescence-Modulating COX Inhibitors
by: Jeong A. Han, et al.
Published: (2017-06-01)

NEW DATA ON THE SAFETY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: THE CONCEPT OF THE HIGH CLASS-SPECIFIC CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS IS OUTDATED
by: A. E. Karateev, et al.
Published: (2017-04-01)

Computational identification of dual COX-1 and NIK inhibitors from marine microalga Chlorella vulgaris
by: Mahesh Samantaray, et al.
Published: (2025-09-01)

Acetyl Salicylic Acid, COX‐2 Inhibitors and Other NSAIDs and Breast Cancer Survival in a Finnish Population‐Based Cohort
by: M. Malin, et al.
Published: (2025-07-01)

Flavocoxid Inhibits Phospholipase A2, Peroxidase Moieties of the Cyclooxygenases (COX), and 5-Lipoxygenase, Modifies COX-2 Gene Expression, and Acts as an Antioxidant
by: Bruce P. Burnett, et al.
Published: (2011-01-01)

COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation
by: John L. Wallace
Published: (2006-01-01)

Immunohistochemical Expression of COX2 in Urothelial Carcinoma of the urinary bladder
by: Shayan Khattab Omer, et al.
Published: (2024-12-01)

COX‐2 in lung cancer: Mechanisms, development, and targeted therapies
by: Xueqi Liu, et al.
Published: (2024-12-01)

New Inference Procedures for Semiparametric Varying-Coefficient Partially Linear Cox Models
by: Yunbei Ma, et al.
Published: (2014-01-01)

Survival analysis of Kasturi tobacco plants in Jember district using the stratified cox and extended cox models.
by: Angga Iryanto Pratama, et al.
Published: (2025-06-01)

Nucleobindin co-localizes and associates with cyclooxygenase (COX)-2 in human neutrophils.
by: Patrick Leclerc, et al.
Published: (2008-05-01)

The interplay between COX-2, chemotherapeutic drugs, and chemoresistance in colon cancer
by: Sally M. Shalaby, et al.
Published: (2025-05-01)

腹水COX-2 mRNA的表达及意义
Published: (2016-01-01)

NEW DIRECTIONS IN THE TREATMENT OF RHEUMATOID ARTHRITIS: MECHANISMS OF ACTION AND CLINICAL EFFICACY OF LEFLUNOMIDE
by: D. V. Reshetniak, et al.
Published: (2001-10-01)

Pulmonary and Cardiorenal Cyclooxygenase-1 (COX-1), -2 (COX-2), and Microsomal Prostaglandin E Synthase-1 (mPGES-1) and -2 (mPGES-2) Expression in a Hypertension Model
by: Zaher A. Radi, et al.
Published: (2007-01-01)

Density Functional Theory and Molecular Docking Investigation of Selected NSAIDs against COX-1 and COX-2 Enzymes: Study of Correlation Between Computational and Experimental Results
by: Ateeq Ullah Jan, et al.
Published: (2025-04-01)

Data-driven prior elicitation for Bayes factors in Cox regression for nine subfields in biomedicine.
by: Maximilian Linde, et al.
Published: (2025-01-01)

Interaction Phloroglucinol as inflammation therapy through Cyclooxygenase-2 (COX-2) gene inhibition
by: Yohanes Bare
Published: (2022-03-01)

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
by: Yue Lu, et al.
Published: (2021-11-01)

Role of COX-2 in the regulation of the metastatic potential of human breast tumor cells
by: M. A. Taipov, et al.
Published: (2014-07-01)

COX PROPORTIONAL HAZARD REGRESSION SURVIVAL ANALYSIS FOR TYPE 2 DIABETES MELITUS
by: Umi Mahmudah, et al.
Published: (2022-03-01)